TY - JOUR
T1 - Intrahepatic Cholestasis of Pregnancy
T2 - Natural History and Current Management
AU - Roediger, Rebecca
AU - Fleckenstein, Jaquelyn
N1 - Publisher Copyright:
© 2021 American Institute of Physics Inc.. All rights reserved.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Intrahepatic cholestasis of pregnancy (ICP) is a common disorder in the second half of pregnancy characterized by pruritus and elevated serum bile acids (BAs) with spontaneous resolution after delivery. ICP carries a risk of adverse effects on the fetus which correlates with the degree of BA elevation. ICP occurs in genetically susceptible women as the reproductive hormones increase during pregnancy. Ursodeoxycholic acid is still considered the first-line treatment for ICP though it is of unproven benefit in preventing adverse effects on the fetus. Fetal complications, such as stillbirth, increase with gestational age, so preterm delivery is generally performed in cases of severe ICP, defined as BA levels above 40 μmol/L. ICP may recur in future pregnancies and is associated with an increased risk for future hepatobiliary, immune mediated, and cardiovascular diseases. Children born of mothers with ICP have normal development but may have a risk for subsequent metabolic disease.
AB - Intrahepatic cholestasis of pregnancy (ICP) is a common disorder in the second half of pregnancy characterized by pruritus and elevated serum bile acids (BAs) with spontaneous resolution after delivery. ICP carries a risk of adverse effects on the fetus which correlates with the degree of BA elevation. ICP occurs in genetically susceptible women as the reproductive hormones increase during pregnancy. Ursodeoxycholic acid is still considered the first-line treatment for ICP though it is of unproven benefit in preventing adverse effects on the fetus. Fetal complications, such as stillbirth, increase with gestational age, so preterm delivery is generally performed in cases of severe ICP, defined as BA levels above 40 μmol/L. ICP may recur in future pregnancies and is associated with an increased risk for future hepatobiliary, immune mediated, and cardiovascular diseases. Children born of mothers with ICP have normal development but may have a risk for subsequent metabolic disease.
KW - cholestasis
KW - pregnancy
KW - pruritus
UR - http://www.scopus.com/inward/record.url?scp=85099824371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099824371&partnerID=8YFLogxK
U2 - 10.1055/s-0040-1722264
DO - 10.1055/s-0040-1722264
M3 - Article
C2 - 33764488
AN - SCOPUS:85099824371
SN - 0272-8087
VL - 41
SP - 103
EP - 108
JO - Seminars in liver disease
JF - Seminars in liver disease
IS - 1
ER -